Ipsen boards ADC train in $900M pact with Sutro

Ipsen has joined the glob­al deal­mak­ing spree for an­ti­body-drug con­ju­gates as the French bio­phar­ma picks up its first as­set in on­col­o­gy’s hottest pock­et of R&D.

The drug­mak­er said Tues­day it will pay up to $900 mil­lion, in­clud­ing about $90 mil­lion in the near term, to snag the ex­clu­sive rights to Sutro Bio­phar­ma’s ROR1-tar­get­ing ADC for sol­id tu­mors.

Sutro priced a $75 mil­lion stock of­fer­ing short­ly af­ter the Bay Area biotech an­nounced the Ipsen deal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER